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Abstract
Background—The development and approval of an efficacious pharmacotherapy for stimulant 
use disorders has been limited by the lack of a meaningful indicator of treatment success, other 
than sustained abstinence.
Methods—In March, 2015, a meeting sponsored by Analgesic, Anesthetic, and Addiction 
Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) was convened 
to discuss the current state of the evidence regarding meaningful outcome measures in clinical 
trials for stimulant use disorders. Attendees included members of academia, funding and 
regulatory agencies, pharmaceutical companies, and healthcare organizations. The goal was to 
establish a research agenda for the development of a meaningful outcome measure that may be 
used as an endpoint in clinical trials for stimulant use disorders.
Results and Conclusions—Based on guidelines for the selection of clinical trial endpoints, 
the lessons learned from prior addiction clinical trials, and the process that led to identification of 
a meaningful indicator of treatment success for alcohol use disorders, several recommendations 
for future research were generated. These include a focus on the validation of patient reported 
outcome measures of functioning, the exploration of patterns of stimulant abstinence that may be 
associated with physical and/or psychosocial benefits, the role of urine testing for validating self-
reported measures of stimulant abstinence, and the operational definitions for reduction-based 
measures in terms of frequency rather than quantity of stimulant use. These recommendations may 
be useful for secondary analyses of clinical trial data, and in the design of future clinical trials that 
may help establish a meaningful indicator of treatment success.
Keywords
Stimulant use disorders; Outcome measures; Clinical trials
1. INTRODUCTION
Sustained abstinence is considered the only outcome currently accepted by the US Food and 
Drug Administration (FDA) as a valid endpoint for clinical trials evaluating 
pharmacotherapies for drug use disorders (FDA: Psychopharmacologic Drugs Advisory 
Committee, 2013; Winchell et al., 2012). However, this endpoint is often considered 
unrealistic, and the lack of meaningful alternative indicators of treatment success (Carroll et 
al., 2014; Donovan et al., 2012) may be one factor that has hindered the development and 
approval of an efficacious pharmacotherapy for stimulant use disorders (see Acri and 
Skolnick, 2013). On March 24th and 25th, 2015, a meeting sponsored by the Analgesic, 
Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and 
Networks (ACTTION), a public-private partnership with the FDA, was convened to discuss 
‘Measures of Outcome for Stimulant Trials’. ACTTION’s mission includes optimizing the 
design and execution of clinical trials to expedite the discovery and development of 
improved treatments. Participants were drawn from clinical investigators, representatives of 
the National Institute on Drug Abuse (NIDA), the National Institute on Alcohol Abuse and 
Alcoholism (NIAAA), the FDA, pharmaceutical companies, and healthcare organizations. 
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The overall goal was to identify a research agenda for the development of outcome measures 
other than sustained abstinence that would be clinically meaningful and could be used as 
endpoints for stimulant use disorder clinical trials. The purpose of this review is to provide a 
summary of the state of knowledge regarding this topic area, as addressed at this meeting, 
and to make recommendations for the field moving forward.
2. CHARACTERISTICS OF A MEANINGFUL OUTCOME MEASURE
The FDA’s Center for Drug Evaluation and Research (CDER) provides specific guidance to 
the research and pharmaceutical communities regarding the selection of endpoints for use in 
clinical trials. CDER has a formal for identifying specific measures that will aid in drug 
development, which include biomarkers and clinical outcome assessments (for more detailed 
information, see Qualification Process for Drug Development Tools, Center for Drug 
Evaluation and Research, 2014). In addition to the need for any assessment tool to have 
strong psychometric properties (e.g., reliability, validity), several aspects of the outcome 
measure should be considered for selection as an endpoint in stimulant trials and are 
discussed below.
Clinical outcome assessments are those that measure a patient’s symptoms or level of 
functioning, and can provide both direct and indirect evidence of treatment response 
(depending on who is reporting the outcome: patient vs. clinician vs. observer). Of the 
various potential clinical outcome assessments possible, the FDA views patient-reported 
outcomes as the nearest to direct evidence for some conditions, as they come directly from 
the patient without interpretation from others. These are formally recommended “when 
measuring a concept best known by the patient or best measured from the patient 
perspective” (from FDA Guidance for Industry document: Patient-Reported Outcome 
Measures: Use in Medical Product Development to Support Labeling Claims). Therefore, a 
patient-reported outcome may provide meaningful evidence of benefit from treatment for 
stimulant use, as the disorder is characterized by a wide variety of problems potentially 
better measured from the patient’s perspective in some cases (more than mere frequency of 
drug consumption). However, in the treatment of stimulant use disorders, there is some 
disagreement regarding the validity of patient-reported drug use, drug-related symptoms and 
problems (Hjorthøj et al., 2012; Magura and Kang, 1996).
While most treatments (pharmacotherapy or behavioral) are designed to affect the target 
behavior of stimulant use, measuring rates of stimulant use may not be the sole indicator of 
treatment success. Treatment benefit is demonstrated by evidence of a positive impact on 
how an individual feels or functions in daily life; a meaningful outcome measure should be 
capable of indicating change in one of these areas. Although changes in biomarkers such as 
urine test results may be useful as an objective indicator of response to a therapeutic 
intervention, they are considered a surrogate (i.e., substitute) for how an individual feels or 
functions in their daily life, and may not be a particularly meaningful outcome of treatment 
for drug use disorders that are characterized by multiple physical and psychosocial 
problems/consequences (e.g., Winchell et al., 2012). Due to the chronic nature of stimulant 
use disorders, demonstrating significant change in physical and psychosocial domains is 
limited by the relatively short duration of most clinical trials. Therefore, a meaningful 
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outcome measure would be a level of reduced drug use that is predictive of long-term 
improvement in an individual’s functioning in these areas. Several clinical trials have 
documented a statistically significant reduction in urine measures of stimulant use; however, 
identification of the specific level of reduced stimulant use (in terms of duration of 
abstinence and/or reduction in frequency of use) that is associated with clinically meaningful 
indices of long-term improvement has not been established.
3. CHALLENGES IN MEASURING REDUCTIONS IN STIMULANT USE
The existence of a valid, biological indicator for detecting stimulant use (i.e., urine testing) 
is a major advantage compared to other psychiatric disorders, yet also has important 
limitations as an outcome measure. In general, detection times for stimulant metabolites in 
urine are up to 2–3 days after the occurrence of drug use (Cone et al., 2003; Oyler et al., 
2002; Preston et al., 2002), yet many additional factors result in substantial variability in the 
ability to detect urine metabolites (e.g., route of administration, dose/purity of drug, 
individual differences in drug metabolism, urine concentration, level of drug use chronicity). 
These factors often create wide variations in metabolite concentrations in urine (e.g., 
concentrations of benzoylecgonine, a cocaine metabolite, can be detected at 150ng/mL but 
concentrations greater than 900,000 ng/mL have been reported in some trials; Preston et al., 
1998, 1997). While using urine drug screen results (or other biological indicators) as a 
primary efficacy endpoint in clinical trials have multiple advantages, strict reliance upon 
urinalysis results for evidence of treatment outcome is not as clear-cut as it may seem. 
Differences in the frequency of sample collection, the type of biological analysis 
(quantitative or qualitative), the threshold for determining abstinence (e.g., 150 vs. 300 
ng/ml of benzoylecgonine), the resolution of discrepancy between biological and self-report 
data, and the handling of missing data all have a profound impact on the validity of the 
outcome measure.
The lack of standard methods for the field regarding these and other issues necessitate 
multiple decisions that influence the interpretation of drug use outcome measures. First, the 
most suitable schedule of urine sample collection to detect stimulant use in clinical trials is 
unresolved. Due to the relatively brief window of detection, urine samples collected only 
once per week may result in an underestimation of stimulant use, yet collection of urines too 
frequently (e.g., 3 times per week) can result in overestimation of stimulant use due to 
carryover (Preston et al., 1997). The level of participant burden should also be considered 
when selecting a urine collection schedule. Second, there is no consensus regarding 
appropriate measurement of self-reported stimulant use. Many researchers create 
dichotomous variables to reflect daily stimulant use (yes/no), yet the lack of standardization 
across drugs, routes of administration, and the methodology used to obtain self-reports limits 
the ability to detect reductions in the quantity of stimulant use. Third, while there is general 
agreement that both self-report and biological results (e.g., urine drug screens) should be 
included in clinical trials with stimulant users (Donovan et al., 2012), combining these 
sources of data is not at all straightforward. The challenge arises when these two sources are 
incongruent or when one source is missing, particularly in instances when the outcome 
measure is a continuous variable (e.g., percentage of days abstinent). Several methods have 
been proposed for resolving the discrepancy through use of algorithms (Oden et al., 2011; 
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Preston et al., 1997; Somoza et al., 2008), but these can be complicated, often requiring 
costly quantitative urinalysis testing, and entail some level of assumptions. This issue is less 
complicated when using a dichotomous outcome measure (e.g., abstinent for at least 4 
weeks), as the presence of a positive urine during the time period would indicate a failure to 
reach that cutoff (Carroll et al., 2014). Finally, regardless of the type of outcome measure 
considered (dichotomous or continuous; self-report or biological), missing data is arguably 
the biggest challenge to defining drug use/abstinence outcomes.
Although missing data are problematic in any clinical trial (Lavori et al., 2008; Siddique et 
al., 2008), the assumptions for handling missing data in drug use trials can lead to very 
different estimates of use and often determine whether an outcome measure detects a 
treatment effect or not (McPherson et al., 2015; Witkiewitz et al., 2014). For instance, rates 
of positive/negative urine drug screen results can vary widely depending on whether missing 
urine results are treated as ‘positive’ or ‘missing’ (e.g., many trials impute missing as 
indicative of ‘positive’ urine result). This is also true for calculation of continuous indicators 
of self-reported cocaine use, such as the percentage of days abstinent, wherein the selected 
denominator is a crucial decision for interpreting results (i.e., whether the denominator is the 
total number of urine samples expected or provided during the course of the trial; Carroll et 
al., 2014). A 2010 report produced by a National Academy of Sciences Panel on the 
Handling of Missing Data in Clinical Trials provides 18 recommendations for addressing 
missing data, noting that the preferred approach to the problem of missing data in clinical 
trials is to avoid missing data in the first place, as all strategies for statistical imputation or 
correction have important limitations including unverifiable assumptions and some level of 
subjectivity (National Research Council, 2010).
An additional challenge in measuring stimulant use as an outcome is in defining meaningful 
change in quantity/frequency of use (i.e., reduction). Because stimulants, such as cocaine 
and methamphetamine, are illicit drugs, there is no normative or established ‘safe’ level of 
use. Given the potential for serious harm due to the acute ingestion of cocaine or 
methamphetamine, it has been suggested that any reduction in the frequency an individual 
engages in this behavior would appear to benefit the individual (McCann et al., 2015). 
Others have argued that reduced use per se provides insufficient evidence of clinical benefit 
(Winchell et al., 2012). Furthermore, there are no standard units for quantifying illicit drugs 
(as there are with alcohol or tobacco), so calculating an outcome measure based on a 
reduction in self-reported quantity becomes virtually impossible. Thus, any definition of 
meaningful change would have to be defined by changes in the frequency (e.g., in days, 
weeks) rather than the amount, which limits the sensitivity of the measure (Carroll et al., 
2014).
4. USING THE ALCOHOL FIELD AS A GUIDE
As there are similarities in the behavioral patterns of drug-taking for stimulants and alcohol 
(i.e., variable patterns that include periods of abstinence and relapse), the process that led to 
the identification of a standard, accepted and valid outcome measure of treatment success 
for alcohol use, ‘percent of subjects with no heavy drinking days’ (PSNHDDs), may serve 
as a useful model for the stimulant outcomes development process. Alcohol 
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pharmacotherapy clinical trials had a similar history as stimulant trials in that numerous 
outcomes were evaluated as efficacy endpoints, largely based on self-reported quantity and 
frequency of drinking rather than psychosocial or physical consequences of alcohol use 
(Falk et al., 2010). Continuous variables, such as the percentage of days abstinent, the 
percentage of heavy drinking days, or total alcohol consumption were the preferred 
measures, with outcomes typically presented as a comparison of group means to determine 
statistical significance. Continuous outcomes like these are desirable since they capture 
changes in the amount and pattern of drinking, and are generally known to have greater 
statistical power to detect a treatment effect than dichotomous outcomes. Yet despite the 
advantages of such continuous outcome measures, they are difficult to interpret in terms of 
clinical benefit or quantifying how many individuals achieved a ‘good outcome’. On the 
other hand, dichotomous outcomes are more readily interpretable, have been promoted to 
increase acceptance of medication effects, and allow for the establishment of guidelines for 
medications development (Carroll et al., 2014; Falk et al., 2014). The most common 
dichotomous outcome in alcohol clinical trials had been the percentage of participants 
abstinent from alcohol. This outcome has traditionally been the primary goal of most 
treatment programs and, until recently, was the only outcome accepted by the FDA for 
Phase 3 registration trials. This indicator has limitations as well, as those who experienced 
minor slips or drank at low-risk levels are deemed treatment failures (Falk et al., 2010).
Notably, the non-abstinence based outcome PSNHDD has now been accepted as a primary 
efficacy endpoint by the FDA based on analyses commissioned by NIAAA on longitudinal 
and observational datasets (Food and Drug Administration Draft Guidance, 2015). Work by 
Falk and colleagues, using data from two sets of alcohol clinical trials, demonstrated that 
PSNHDD at the end of treatment (given various grace period lengths, as discussed below) 
was associated with fewer alcohol-related consequences and lower levels of drinking during 
a 1-year follow-up period (Falk et al., 2010). Although the ‘low-risk’ drinking group (i.e., 
those with no HDDs but continued alcohol use) had worse follow-up drinking outcomes 
than those who were completely abstinent, they fared significantly better than those who had 
HDDs, thereby validating this non-abstinence based outcome as associated with fewer 
subsequent psychosocial and physical consequences. This outcome is further supported 
through: prospective study data indicating the frequency of heavy drinking increased the 
relative risks of mortality from cardiovascular disease and cancer (Breslow and Graubard, 
2008), epidemiologic data indicating individuals with no heavy drinking days had a lower 
risk for developing alcohol dependence and alcohol use disorders than those who 
experienced heavy drinking days (Dawson et al., 2007), as well as through data from 
treatment centers indicating low-risk drinkers were similar to abstinent individuals with 
respect to long-term psychosocial outcomes (Kline-Simon et al., 2013) and treatment 
utilization and costs (Kline-Simon et al., 2014).
Two important aspects of the Falk et al. study validating PSNHDD that may be useful for 
identifying an outcome measure for stimulant trials are: (1) the evaluation of various grace 
periods that impacted the treatment’s effect size, and (2) the use of the Drinker Inventory of 
Consequences (DRINC; Miller et al., 1995) as a measure of alcohol-related consequences. 
First, in the alcohol studies it was found that the detected differences between an active drug 
and placebo increased with each additional month of a grace period, such that the largest 
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effects were found in the final month of treatment (i.e., the longer the grace period, the 
larger the end of treatment effect). By discounting slips during an initial period of 
pharmacotherapy, a grace period may offer greater sensitivity for detecting success/failure 
outcomes in stimulant trials (McCann et al., 2015; McCann and Li, 2012). Second, a tool for 
assessing physical and psychosocial consequences of alcohol use (e.g., the DRINC) was 
sensitive to changes in alcohol use, and was able to differentiate low-risk from high-risk 
drinking. Although a parallel instrument has been developed to assess the consequences of 
drug use, the Inventory of Drug Use Consequences (InDUC; Tonigan and Miller, 2002), it is 
not specific for stimulant use (items refer to consequences of drinking or drug use) and is 
rarely included within stimulant treatment clinical trials.
There are three advantages that the alcohol field has relative to clinical trials for stimulant 
use disorders. The first is an accepted measure of a standard drink, given the clear and 
known size and alcohol content of different marketed beverages. Given that they are illicit, 
stimulants such as cocaine and methamphetamine have no similar standard approach to 
sizing and purity. Second, the alcohol field developed the concept of a ‘heavy drinking day’ 
that has been linked to alcohol-related consequences (Breslow and Graubard, 2008; Jackson, 
2008). No such analogue has been developed for stimulant use. Third, medications (such as 
naltrexone) with established efficacy in the treatment of alcohol use disorders are available 
for use in validating clinical trial endpoints. Such medications are lacking for the treatment 
of stimulant use disorders.
5. WHERE ARE WE NOW?
NIDA has been particularly interested in the potential validation of an outcome measure 
other than sustained abstinence (e.g., ‘intermittent abstinence’ or ‘reduction in use’) that is 
clinically meaningful (i.e., associated with improvements in physical or psychosocial 
functioning) for use in clinical trials of pharmacotherapies for cocaine and 
methamphetamine use disorders. Several funding opportunities have been issued in recent 
years to address this area, and some resulting studies have produced promising findings 
(e.g., Carroll et al., 2014; Crits-Christoph et al., 2013; Garner et al., 2014; Kiluk et al., 2014; 
Lai et al., 2015). For instance, using pooled data from 5 randomized controlled trials of 
treatment for cocaine dependence, Carroll and colleagues (2014) identified several 
continuous (e.g., percentage of days abstinent, percentage of negative urine samples, 
maximum days of continuous abstinence), and dichotomous (e.g., achieving at least 3 weeks 
of continuous abstinence) measures that were significantly associated with cocaine use and a 
measure of ‘good functioning’ (defined as 0 days cocaine use, and 0 days of legal, 
employment, and psychological problems as reported on the Addiction Severity Index – 
ASI; McLellan et al., 1992) during a 12-month follow-up period. In a complementary 
analysis with the same dataset, Kiluk and colleagues (2014) used longitudinal growth curve 
modeling to demonstrate greater rates of abstinence during treatment (indicated by 
continuous or dichotomous measures) were associated with fewer reported problems across 
all ASI domains (‘global problems’) during follow-up. Although the magnitude of these 
relationships in both analyses were relatively modest, the findings hold promise for the use 
of a dichotomous outcome measure [≥ 3 weeks of continuous abstinence, which is an 
outcome measure used in some of the earliest trials for cocaine dependence (Gawin et al., 
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1989)] as an indicator of treatment success, as it has been associated with less cocaine use 
and fewer physical and psychosocial problems in the long term.
There is also promising evidence that a reduction in cocaine use can have health benefits. 
For example, Lai and colleagues (2015) in a pilot study reported both cocaine abstinence 
and reduction in cocaine use (indicated by self-reported days of use) were associated with a 
decrease in endothelin-1 (ET-1), which is a marker of endothelial dysfunction and damage 
(and can contribute to hypertension and cardiac disease). Furthermore, the study found that 
the number of days of cocaine use was positively associated with ET-1 levels. This 
association held after controlling for family history of heart attack, baseline ET-1, and 
cardiovascular risk profile, suggesting a reduction in the number of days of cocaine use is 
independently associated with less endothelial damage. Although preliminary due to small 
sample size (n=57), these results offer promise for ET-1 as a potentially valid health 
outcome measure for medication trials that target cocaine use (McCann et al., 2015). For a 
thorough review of the evidence regarding biomarkers for cocaine use disorders, see Bough 
et al. (2014).
In terms of potential clinical outcome assessments for stimulant trials, the Cocaine Selective 
Severity Assessment (CSSA; Kampman et al., 1998) has been evaluated as an indicator of 
cocaine treatment benefit. The CSSA has been found to be a valid and reliable indicator of 
cocaine withdrawal syndrome (Gawin and Kleber, 1986), and several trials have found it 
predictive of poor treatment response (e.g., Ahmadi et al., 2006; Kampman et al., 2001, 
2002). However, despite the CSSA’s strong sensitivity at identifying poor treatment 
responders, its specificity at identifying patients likely to do well is fairly low, thereby 
limiting its utility as an outcome measure for clinical trials. The CSSA may be more useful 
as a stratification variable in study design of the clinical trial, or as a potential moderator in a 
Phase III medication trial that may inform labelling of medication effects. The ASI 
(McLellan et al., 1992) is another clinical outcome assessment that has been widely used in 
clinical trials with stimulant users, and has sound psychometric characteristics as a reliable 
and valid measure of severity (Alterman et al., 2007; McLellan et al., 2006). However, 
despite the clinical utility of the ASI, it has several limitations as an indicator of treatment 
success in clinical trials (Makela, 2004); most notably, the restricted functional range in 
scores found for most non-drug use problem areas limits the sensitivity to detect 
improvements due to treatment. Whereas treatments may demonstrate an effect on the 
frequency of stimulant use, improvements have not generally extended to the ASI composite 
scores representing psychosocial and other addiction-related problem areas (e.g., Crits-
Christoph et al., 2001).
5.1 Perspectives to consider
As the field continues to evaluate potential outcome measures for use in stimulant clinical 
trials, it is important to consider/integrate the perspectives from various stakeholders 
including regulatory agencies, third party payers, healthcare organizations, and patients as to 
what might be considered meaningful. Notably, payers and the public generally see the 
meaningful outcome as abstinence; reductions in drug use (as opposed to reductions in 
alcohol use) are not as accepted as a good outcome. For instance, data presented at the 
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meeting regarding responses to a double-blinded online survey conducted with a sample of 
34 payers (pharmacy and medical directors from US managed care plans) indicated the 
highest rated concepts in terms of value to their formulary decision-making process for new 
stimulant addiction pharmacotherapies were: (1) abstinence, (2) an effect on healthcare 
resource use (e.g., emergency room visits and hospitalizations), and (3) an impact on 
comorbidities (Duhig, 2015). Certainly, abstinence is not questioned as a meaningful 
endpoint for clinical trials, as it is the goal of most behavioral treatments and 
pharmacotherapies. However, the value of the impact on comorbidities and resource use is 
noteworthy, as these outcomes are not often measured or reported in clinical trials of 
pharmacotherapies for stimulant use. Most early stage pharmacotherapy trials exclude 
individuals with medical and/or psychiatric comorbidities in order to limit the impact on the 
potential effect of the medication under study. Also, while studies have indicated drug use 
treatment can reduce emergency department utilization and hospital admissions (Laine et al., 
2001, 2005), determining the relative cost-benefit of pharmacotherapies in clinical trials is 
complicated by the relatively small numbers of subjects enrolled, the short duration of the 
trials, and the lag between treatment and health care benefits.
A meaningful outcome from a regulatory perspective should also be considered. In the Code 
of Federal Regulations, Title 21 Part 314, regarding the application for FDA approval to 
market a new drug, there is the potential to receive accelerated approval of new drugs for 
serious or life-threatening illnesses based on a surrogate endpoint or an effect on a clinical 
endpoint other than survival or irreversible morbidity (SECTION 314.510). This regulation 
states “FDA may grant marketing approval for a new drug product on the basis of adequate 
and well-controlled clinical trials establishing that the drug product has an effect on a 
surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, 
pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on 
a clinical endpoint other than survival or irreversible morbidity. (http://
www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?
cfrpart=314&showfr=1&subpartnode=21:5.0.1.1.4.8). Again, as drug use during the brief 
window of a clinical trial is considered a surrogate endpoint (Winchell et al., 2012), the goal 
should be to demonstrate that some measure of drug abstinence (or reduced use) is 
‘reasonably likely’ to be predictive of clinical benefit, such as improved physical or 
psychosocial functioning. However, the question remains: what specific duration of 
abstinence and what type of physical or psychosocial outcome assessment would be 
meaningful and/or persuasive to accept a pharmacotherapy as efficacious?
6. CONCLUSIONS AND RECOMMENDATIONS
Considering the guidance of the FDA’s CDER (Center for Drug Evaluation and Research, 
2014), the lessons learned from other addiction trials, and the process of identifying a valid 
endpoint for measuring treatment success in alcohol use clinical trials, the following 
conclusions and recommendations are proposed (see Table 1):
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7. SUMMARY
This ACTTION-sponsored meeting brought together participants from academia, FDA, 
NIDA, NIAAA, and healthcare and pharmaceutical organizations with the targeted goal of 
generating a research agenda for the field of stimulant use. The goal was to move toward 
identifying a clinically meaningful outcome measure, other than long-term abstinence, for 
use in stimulant treatment clinical trials. The participants agreed that the alcohol treatment 
outcome measure (PSNHDD) development was a helpful guide in the quest to validate a 
similar endpoint for the treatment of stimulant use disorders. Patterns of stimulant use are 
not dissimilar from patterns of alcohol use, and there are some parallels in the handling of 
missing data in clinical trials. However, there are also challenges unique to measuring 
stimulant use that require careful consideration of the various methods to identify a valid 
outcome measure. Through discussion of these challenges, review of the current state of the 
evidence, and attention to the perspectives of multiple stakeholders, a list of research 
recommendations for generating a meaningful endpoint to be used in clinical trials for 
stimulant use disorders was developed. Although this is not the first time a list of research 
recommendations have been proposed from an expert panel or task force regarding 
meaningful outcome measures in drug use clinical trials (e.g., Clinical Trials Network, 2010; 
Donovan et al., 2012; Tiffany et al., 2012), the current list represents both an expansion and 
refinement of prior recommendations based on the knowledge gained in recent years and the 
feedback generated from various stakeholders. The above recommendations should be 
considered a blueprint, for both the design of future clinical trials, as well as for potential 
secondary analyses of stimulant use clinical trial data intended to reveal evidence of 
meaningful treatment benefit to advance the development/approval of new drugs to treat 
stimulant use disorders.
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Highlights
• Meaningful outcome measures, other than sustained abstinence, would be 
beneficial.
• There are multiple challenges unique to measuring stimulant use.
• Meaningful alternative outcomes should be associated with functional benefits.
• A patient reported outcome may be useful for validating a stimulant use 
endpoint.
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Table 1
Conclusions and Recommendations
Conclusions Recommendations for future research
1. Qualified Patient Reported Outcomes are accepted by the FDA 
for measuring treatment benefit, and may be used to validate a 
measure of stimulant use as a surrogate endpoint that is 
reasonably likely to predict clinical benefit. This would parallel 
the alcohol field’s use of the DRINC as a tool for validating 
PSNHDD as a meaningful endpoint.
Emphasis should be placed on the development or modification of a 
standardized Patient Reported Outcome instrument for measuring the 
physical and psychosocial problems/consequences that characterize 
stimulant use disorders. Such an instrument should demonstrate 
sensitivity to changes in stimulant use.
2. Long-term abstinence should remain the goal of treatments for 
stimulant use disorders, and the target endpoint for clinical trials. 
However, alternative outcomes (e.g., periods of ‘intermittent 
abstinence’) should be evaluated with respect to associated 
functional outcomes.
Secondary analysis of clinical trial data should compare various patterns 
of stimulant use (e.g., 1–4 days per month vs. >4 days per month) and the 
associated physical and psychosocial consequences. This may help define 
a pattern of ‘intermittent abstinence’ that is associated with more 
favorable physical or psychosocial outcomes as compared to ‘regular use’ 
(in the same manner that low-risk drinkers had more favorable outcomes 
compared to heavy drinkers).
3. Measures of ‘reduction’ in stimulant use that are based on the 
quantity of use per day (either through self-report or quantitative 
urinalysis) are too unreliable for consideration as a valid outcome 
measure. There does not appear to be a stimulant use equivalent 
of a ‘heavy drinking day’ in terms of amount consumed per day.
Reduction-based measures defined by a reduction in the quantity of use 
per day/episode (self-report or urinalysis) should be abandoned. Any 
measure of reduction should be based on the frequency of days of 
stimulant use (either per week or per month).
4. Urine drug screens should continue to be an essential 
component of clinical trials for stimulant use disorders. However, 
they should mainly be used to corroborate self- reported use/
abstinence, rather than as a primary outcome measure (i.e., 
moving away from a primary emphasis on comparing the 
percentage of positive/negative urine results across treatment 
conditions).
In clinical trials, urine collection might be limited to once per week 
during the treatment period to confirm abstinence and reduce participant 
burden. Future trials might also explore the use of contingency 
management procedures to increase the accuracy of self- reported 
stimulant use (e.g., provide $10 voucher if urine result matches self-
report).
5. Missing data are one of the biggest threats to measurement of 
stimulant use/abstinence in clinical trials. All methods of 
statistical imputation to handle missing data include subjective 
assumptions. The best way to handle missing data is to limit it as 
much as possible.
All methods for collecting data from treatment drop-outs should be 
utilized. This includes: providing transportation to/from appointments, 
offering alternate locations for assessment interviews, obtaining 
permission to contact significant others who might know how to contact 
the individual if staff unable to do so, and incorporating multiple methods 
of communication with participants (e.g., phone, text message, email, 
social media, and postal mail). Persistence is key in this endeavor (Cottler 
et al., 1996; Farabee et al., 2011; Festinger et al., 2008; Kleschinsky et al., 
2009; Scott, 2004)
6. The existence of an established efficacious medication for 
reducing alcohol use facilitated the process of validating a 
meaningful outcome measure for use in clinical trials for the 
treatment of alcohol use disorders. Although such a medication 
does not exist for stimulant use disorders, there are behavioral 
treatments with established efficacy at reducing stimulant use 
(e.g. Contingency Management) that may be useful for validating 
an outcome measure.
Data from contingency management trials for stimulant use disorders 
could be used for defining an outcome measure that is indicative of 
treatment success. Such a measure could then be used to evaluate success 
in pharmacotherapy trials.
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